MétaCan
Menu
← Back to cohort
Record W4415665469 · doi:10.51731/cjht.2025.1274

Mirvetuximab Soravtansine (Elahere)

2025· article· W4415665469 on OpenAlexaboutno aff
CDA-AMC

Bibliographic record

VenueCanadian Journal of Health Technologies · 2025
Typearticle
Language
FieldMedicine
TopicPARP inhibition in cancer therapy
Canadian institutionsnot available
Fundersnot available
KeywordsFallopian tubeCancerDiseaseFallopian tube cancerPrimary careDrugFirst line

Abstract

fetched live from OpenAlex

Canada’s Drug Agency (CDA-AMC) recommends that Elahere be reimbursed by public drug plans for the treatment of adults with FR-alpha–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic treatment regimens if certain conditions are met. Elahere should only be covered to treat patients with a confirmed diagnosis of epithelial ovarian, primary peritoneal, or fallopian tube cancer who have platinum-resistant disease, a tumour that is positive for FR-alpha expression confirmed by a validated test, disease that progressed on or after their most recent line of therapy, and received at least 1 prior systemic line of anticancer therapy. Elahere should only be reimbursed if the patient is under the care of a physician with expertise in managing gynecological malignancies, if the treatment is administered in an oncology health facility with access to ophthalmic services and FR-alpha testing, and if the cost of Elahere is reduced.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.998
Threshold uncertainty score0.063

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0190.004

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.029
GPT teacher head0.344
Teacher spread0.315 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueCanadian Journal of Health Technologies→Same topicPARP inhibition in cancer therapy→French-language works237,207→